Structure Therapeutics
Qinghua Meng has a diverse and extensive work experience in the field of chemistry. They started their career as a Scientist (D4) at GSK in June 2008 and worked in that role until April 2011. After that, they took on the role of Scientist (D3) at GSK from May 2011 to October 2013. From November 2013 to March 2015, they served as a Senior Scientist at GSK. Then, they joined Eli Lilly China as a Principal Scientist in April 2015 and stayed there until October 2017. Subsequently, Qinghua Meng worked as the Head of Chemistry at Beijing Kuling from November 2017 to September 2019. Currently, they hold the position of Senior Director of Chemistry at ShouTi, where they started in September 2019 and have since been promoted to the role of Director of Chemistry, starting in July 2021.
Qinghua Meng obtained a Bachelor's degree in Environmental Science from Shandong University in 2002. Following that, from 2002 to 2005, Qinghua pursued a Master's degree in Organic Chemistry at East China University of Science and Technology. Continuing their academic journey, Qinghua completed their education by obtaining a Doctor of Philosophy (Ph.D.) in applied chemistry from Shanghai Jiao Tong University between the years 2005 and 2008.
This person is not in any offices
Structure Therapeutics
Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations inbiologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.